These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 18021495

  • 1. Improving glycemic control with insulin detemir using the 303 Algorithm in insulin naïve patients with type 2 diabetes: a subgroup analysis of the US PREDICTIVE 303 study.
    Selam JL, Koenen C, Weng W, Meneghini L.
    Curr Med Res Opin; 2008 Jan; 24(1):11-20. PubMed ID: 18021495
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Basal-bolus therapy with insulin detemir using the 303 algorithm in the US PREDICTIVE 303 trial.
    Selam JL, Meneghini LF.
    Adv Ther; 2009 Feb; 26(2):194-207. PubMed ID: 19259629
    [Abstract] [Full Text] [Related]

  • 4. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
    Hollander P, Cooper J, Bregnhøj J, Pedersen CB.
    Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
    [Abstract] [Full Text] [Related]

  • 5. Once-daily insulin detemir in a cohort of insulin-naïve patients with type 2 diabetes: a sub-analysis from the PREDICTIVE study.
    Meneghini LF, Dornhorst A, Sreenan S, PREDICTIVE Study Group.
    Curr Med Res Opin; 2009 Apr; 25(4):1029-35. PubMed ID: 19281426
    [Abstract] [Full Text] [Related]

  • 6. The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes--results of the randomized, controlled PREDICTIVE 303 study.
    Meneghini L, Koenen C, Weng W, Selam JL.
    Diabetes Obes Metab; 2007 Nov; 9(6):902-13. PubMed ID: 17924873
    [Abstract] [Full Text] [Related]

  • 7. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study.
    Meneghini LF, Rosenberg KH, Koenen C, Merilainen MJ, Lüddeke HJ.
    Diabetes Obes Metab; 2007 May; 9(3):418-27. PubMed ID: 17391170
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Improvement of glycemic control with addition of insulin detemir to existing antidiabetic therapy: a sub-group analysis of A1chieve observational study.
    Kesavadev J, Joshi SR.
    J Assoc Physicians India; 2013 Jan; 61(1 Suppl):28-30. PubMed ID: 24482985
    [Abstract] [Full Text] [Related]

  • 12. Comparison of efficacy and safety of once- versus twice-daily insulin detemir added on to oral antidiabetics in insulin-naive type 2 diabetes patients: 24-week, crossover, treat to target trial in a single center.
    Cander S, Dizdar OS, Oz Gul O, Guclu M, Unal OK, Tuncel E, Erturk E, Imamoglu S, Ersoy C.
    Prim Care Diabetes; 2014 Oct; 8(3):256-64. PubMed ID: 24522170
    [Abstract] [Full Text] [Related]

  • 13. Insulin Detemir in Combination with Oral Antidiabetic Drugs Improves Glycemic Control in Persons with Type 2 Diabetes in Near East Countries: Results from the Lebanese Subgroup.
    Echtay A, Andari E, Atallah P, Moufarrege R, Nemr R.
    Ethn Dis; 2017 Jan 19; 27(1):45-54. PubMed ID: 28115821
    [Abstract] [Full Text] [Related]

  • 14. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart.
    Vague P, Selam JL, Skeie S, De Leeuw I, Elte JW, Haahr H, Kristensen A, Draeger E.
    Diabetes Care; 2003 Mar 19; 26(3):590-6. PubMed ID: 12610006
    [Abstract] [Full Text] [Related]

  • 15. A randomized, treat-to-target trial comparing insulin lispro protamine suspension and insulin detemir in insulin-naive patients with Type 2 diabetes.
    Fogelfeld L, Dharmalingam M, Robling K, Jones C, Swanson D, Jacober S.
    Diabet Med; 2010 Feb 19; 27(2):181-8. PubMed ID: 20546262
    [Abstract] [Full Text] [Related]

  • 16. Comparison of insulin lispro protamine suspension and insulin detemir in basal-bolus therapy in patients with Type 1 diabetes.
    Chacra AR, Kipnes M, Ilag LL, Sarwat S, Giaconia J, Chan J, COMPLETE T1D investigators.
    Diabet Med; 2010 May 19; 27(5):563-9. PubMed ID: 20536953
    [Abstract] [Full Text] [Related]

  • 17. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen.
    Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J.
    Clin Ther; 2004 May 19; 26(5):724-36. PubMed ID: 15220016
    [Abstract] [Full Text] [Related]

  • 18. Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes.
    Meneghini L, Kesavadev J, Demissie M, Nazeri A, Hollander P.
    Diabetes Obes Metab; 2013 Aug 19; 15(8):729-36. PubMed ID: 23421331
    [Abstract] [Full Text] [Related]

  • 19. [Once daily insulin detemir in patients with type 2 diabetes: results of German centers in a 6-month international observational study (SOLVE)].
    Liebl A, Wilhelm B, Kaiser M.
    MMW Fortschr Med; 2012 Dec 17; 154 Suppl 4():102-9. PubMed ID: 23326928
    [Abstract] [Full Text] [Related]

  • 20. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.
    Riddle MC, Rosenstock J, Gerich J, Insulin Glargine 4002 Study Investigators.
    Diabetes Care; 2003 Nov 17; 26(11):3080-6. PubMed ID: 14578243
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.